An overview of Eastern Cooperative Oncology Group stage III non-small cell lung cancer studies.
The Eastern Cooperative Oncology Group conducts phase II and III trials for the treatment of resectable and unresectable stage III non-small cell lung cancer, and also participates in a number of Intergroup studies. For resectable disease, the Eastern Cooperative Oncology Group is participating in a phase III prospective randomized, double-blind, placebo-controlled trial of the epidermal growth factor receptor antagonist gefitinib (ZD1839), a phase II trial for superior sulcus tumors of induction chemoradiotherapy with cisplatin/etoposide followed by surgical resection, followed by docetaxel. For unresectable disease, a phase III trial of carboplatin, paclitaxel, and thoracic radiation therapy with or without thalidomide is underway. Proposed studies include a feasibility phase II study of chemotherapy/hyperfractionated accelerated radiation therapy (HART) + cetuximab (an antibody specific for epidermal growth factor receptor) and a phase II trial of pharmcogenomics-directed adjuvant chemotherapy for completely resected non-small cell lung cancer.
Ettinger
David S
DS
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, Baltimore, MD 21231-1000, USA. ettinda@jhmi.edu
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000628:therapy*; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D000077156:Gefitinib; D006801:Humans; D047908:Intracellular Signaling Peptides and Proteins / Q000627:therapeutic use*; D008175:Lung Neoplasms / Q000628:therapy*; D011799:Quinazolines / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D047908:Intracellular Signaling Peptides and Proteins; D011799:Quinazolines; C015482:protein kinase modulator; D066246:ErbB Receptors; D000077156:Gefitinib